This leadership vacuum follows another significant departure at the FDA. Peter Marks, former head of the Center for Biologics Evaluation and Research who worked closely with Verdun on establishing new ...

Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow ...

Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research ...

Capricor Therapeutics has received an orphan drug designation for its drug aimed at potentially treating Becker Muscular Dystrophy. The biotechnology company said Tuesday that the Food and Drug ...

U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s ...

Benzinga's options scanner spotted 10 options trades for Capricor Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 20% bullish and 70% bearish. Among ...

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

Capricor Therapeutics' rating was downgraded amid FDA inspection risks, regulatory uncertainty, and potential delays in ...

Capricor Therapeutics shares dropped after the U.S. FDA inspected its San Diego manufacturing facility. Read more here.

Investing.com -- Capricor Therapeutics Inc (NASDAQ: CAPR) stock tumbled 10.5% after the company announced that the FDA’s inspection of its San Diego manufacturing facility resulted in a Form 483 with ...